A number of other drugs have been tried, including tricyclic antidepressants, theophylline, dronabinol, combined atomoxetine plus oxybutynin (16), but cannot be recommended because of factors including limited experience, a low therapeutic index, lack of replication of results, and lack of adequate trials.